Abbott

Abbott is a global healthcare company led by Chairman and CEO Robert B. Ford. Its portfolio connects medical devices, diagnostics, nutrition, and established medicines, serving needs that range from glucose monitoring and cardiovascular care to laboratory testing and everyday nutrition.

What makes Abbott matter now is not one product cycle. It is the company's ability to turn research into regulated, manufactured, and distributed healthcare technology at global scale. Abbott reported $44.3B in 2025 sales, invested $2.9B in R&D, and completed its acquisition of Exact Sciences in March 2026, adding a larger cancer-diagnostics engine to an already broad platform.

About Abbott

Abbott began in Chicago in 1888, when physician Dr. Wallace C. Abbott started producing accurately dosed medicines. The company that grew from that pharmacy is now headquartered at Abbott Park in Lake County, Illinois, and says its products reach more than 2B people across more than 160 countries.

Robert B. Ford has served as Abbott's CEO since March 2020 and as Chairman since December 2021. His earlier leadership roles included President and COO and Executive Vice President of Medical Devices, experience that matters as medical devices remain a major driver of Abbott's growth and innovation pipeline.

A Portfolio Built Around the Health Journey

Abbott's breadth is easier to understand when viewed through a patient journey rather than a corporate organization chart. The company's products and solutions include FreeStyle Libre continuous glucose monitors, cardiovascular devices and therapies, diagnostic systems for laboratories and care settings, nutrition brands such as Similac, Ensure, Glucerna, and PediaSure, pain and movement therapies, biowearables, and medicines sold in emerging markets.

Those businesses sit in different purchasing systems and regulatory categories, but they address related decisions. A sensor can surface a daily health signal, a diagnostic test can support an earlier clinical choice, and a medical device can create a less invasive treatment path. Abbott's strategic advantage is its ability to operate across those moments without pretending healthcare is a single-product market.

Why Abbott Matters Right Now

Abbott reported Q2 2026 sales of $12.6B and adjusted diluted EPS of $1.31, both above its expectations. The company also raised full-year adjusted EPS guidance while reaffirming comparable sales-growth guidance of 6.5% to 7.5%.

Medical devices, cancer diagnostics, and established pharmaceuticals are carrying much of that momentum. The signal for operators is that healthcare demand remains durable, but the winners still need a productive pipeline, clinical evidence, regulatory execution, manufacturing capacity, and distribution. Abbott has spent decades assembling those capabilities, giving new products a path from scientific idea to real-world use.

Cancer Diagnostics Expands the Platform

Abbott completed its acquisition of Exact Sciences on March 23, 2026. The combination brings Cologuard and Cancerguard into Abbott's diagnostics business and gives the company a stronger position in cancer screening and precision oncology. The strategic goal is to expand access to earlier detection and more personalized care.

The acquisition also illustrates the logic of Abbott's portfolio. Better cancer testing is not valuable because it produces more data; it is valuable because it can help move care earlier, when information has more power to influence a decision. Abbott's global diagnostics relationships and operating scale give Exact Sciences' testing portfolio a broader platform for that work.

Innovation at Institutional Scale

Abbott invested $2.9B in R&D in 2025. That commitment supports work across electrophysiology, structural heart, diabetes care, diagnostics, neuromodulation, nutrition, and other health categories where technical novelty is only the beginning of the job.

Healthcare innovation must survive a longer obstacle course than a consumer feature. Products need evidence, quality systems, regulatory review, clinician confidence, reliable manufacturing, reimbursement pathways, and patient trust. Abbott's durable advantage is the institutional machinery required to move through that course repeatedly. Its risk is the same one every large institution faces: scale only matters if it can keep converting science into better outcomes.

Leadership, Team, and Hiring Momentum

Abbott reports a workforce of 122,000 people, including Exact Sciences after the acquisition. Its careers platform reflects the range of disciplines behind the portfolio, including science, engineering, manufacturing, quality, regulatory work, clinical functions, operations, and technology.

That hiring surface should be read as an operating signal, not an employer-branding slogan. A healthcare company cannot scale sensors, diagnostics, devices, nutrition, and medicines with one type of talent. It needs teams capable of connecting discovery to validation, production, access, and support, often across multiple countries and healthcare systems.

What Abbott Signals for Health Technology

The health-tech market often celebrates the visible layer: the app, the sensor, the test result, or the device in a clinician's hand. Abbott is a reminder that the invisible layer is just as important. Quality systems, supply chains, regulatory fluency, clinical relationships, and patient trust determine whether an invention becomes part of healthcare or remains an impressive demonstration.

For founders, operators, and investors, Abbott represents a useful counterweight to novelty culture. The next era of healthcare will need new ideas, but it will also reward organizations that can connect invention to evidence and evidence to access. Nearly 140 years after its founding, Abbott's relevance depends on continuing to make that connection at a scale few companies can match.